Zila Appoints O. B. Parrish to Its Board of Directors and Audit Committee
June 28 2007 - 4:02PM
Business Wire
Zila, Inc. (NASDAQ GM: ZILA), has appointed O. B. Parrish to its
Board of Directors. Mr. Parrish will also join the Audit Committee.
Mr. Parrish, 73, is the Chairman and CEO of the Female Health
Company, the developer of the first female condom. In collaboration
with the World Health Organization, the United Nations Joint
Program on AIDS and other public sector groups, the FC Female
Condom is distributed worldwide as part of HIV/AIDS prevention
programs. Mr. Parrish is also the President of Phoenix Health Care
of Illinois, Inc. a private company which invests in innovative
healthcare opportunities. In addition, Mr. Parrish is the Chairman
of Abiant, Inc. of Chicago, which provides proprietary neuroimaging
technology to the pharmaceutical industry for use in selecting and
developing new drugs. Earlier in his career Mr. Parrish was the
President of the Pharmaceutical Group of G.D. Searle in Chicago
where he was responsible for its global pharmaceutical business.
Prior to joining Searle, Mr. Parrish was Executive Vice President
of the International Division of Pfizer, Inc, in New York. Other
positions held at Pfizer included Executive Vice President of
Pfizer Pharmaceuticals, Division Manager and Vice President,
Marketing of Pfizer Laboratories. David R. Bethune, Chairman of the
Board of Zila, commented, "O. B. Parrish has extensive experience
in the healthcare and pharmaceutical industries and will contribute
significantly to the continued growth of Zila's oral cancer
screening business." Mr. Parrish holds a B.S degree from Lawrence
University and an M.B.A. degree from the University of Chicago. Mr.
Parrish is also a trustee of Lawrence University. About Zila, Inc.
Zila, Inc., headquartered in Phoenix, is an oral cancer screening
company focused on the prevention and treatment of oral disease.
Zila is dedicated to establishing ViziLite(R) Plus as the new
standard of care within the medical community for the early
detection of oral abnormalities that could lead to cancer, with an
initial focus on the dental market through Pro-Dentec(R), a leading
designer, manufacturer and marketer of Soft Tissue Management
(STM(R)) products. Sold exclusively and directly to dental
professionals, Pro-Dentec's core products include the Rota-dent(R)
Professional Powered Brush, the Pro-Select3(R) Piezo-Ultrasonic
Scaler System and a suite of pharmaceutical STM(R) products for
both in-office and home-care use. For more information about Zila,
visit www.zila.com. Safe Harbor Statement This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These forward-looking statements are based
largely on Zila's expectations or forecasts of future events, can
be affected by inaccurate assumptions and are subject to various
business risks and known and unknown uncertainties, a number of
which are beyond the Company's control. Therefore, actual results
could differ materially from the forward-looking statements
contained herein. A wide variety of factors could cause or
contribute to such differences and could adversely impact revenues,
profitability, cash flows and capital needs. There can be no
assurance that the forward-looking statements contained in this
press release will, in fact, transpire or prove to be accurate, and
we disclaim any obligation to update or revise any such
forward-looking statements. For a more detailed description of
these and other cautionary factors that may affect Zila's future
results, please refer to the documents we file with the Securities
and Exchange Commission, including our Form 10-K for the fiscal
year ended July 31, 2006, our Current Report on Form 8-K filed on
December 28, 2006, and our Form 10-Q for the quarter ended April
30, 2007.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From May 2024 to Jun 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2023 to Jun 2024